Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × NSCLC × rezivertinib × Clear all

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

NSCLC 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

osimertinib 2 Vinorelbine 2 HMPL-013 2 Gefitinib 2 tislelizumab 1 sulindac sulfone 1 rezivertinib 1 anlotinib 1 Radiotherapy 1 Platinum 1 Pemetrexed 1 Paclitaxel 1 Liquid Biopsy 1 Gemcitabine 1 Cisplatin 1 Cetuximab 1 Carboplatin 1 CP protocol 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03812809 2022-05-19

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

Beta Pharma, Inc.

Phase 2 Completed

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡